Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer-Reference-Cited by-同舟云学术

Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer

Published:2023-09-05 Issue:6 Volume:483 Page:855-863
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Miyakoshi Jun,Yazaki Shu,Shimoi Tatsunori,Onishi Mai,Saito Ayumi,Kita Shosuke,Yamamoto Kasumi,Kojima Yuki,Sumiyoshi-Okuma Hitomi,Nishikawa Tadaaki,Sudo Kazuki,Noguchi Emi,Murata Takeshi,Shiino Sho,Takayama Shin,Suto Akihiko,Fujiwara Yasuhiro,Yoshida Masayuki^ORCID,Yonemori Kan

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00428-023-03634-2.pdf

Reference26 articles.

1. Howard FM, Olopade OI (2021) Epidemiology of triple-negative breast cancer: a review. Cancer J 27(1):8–16. https://doi.org/10.1097/PPO.0000000000000500

2. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt. 1):4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045

3. Schmid P, Rugo HS, Adams S et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44–59. https://doi.org/10.1016/S1470-2045(19)30689-8

4. Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9

5. Hoda RS, Brogi E, Dos Anjos CH et al (2020) Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Mod Pathol 33(11):2221

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing Immune Checkpoint Inhibitors Against Gastric Cancer: Charting the Course to Expanded Therapeutic Benefit;Biomedical Research and Therapy;2024-04-30

2. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance;Cancer Research and Treatment;2023-12-12